ACAD
ACADIA Pharmaceuticals Inc.·Healthcare
21.19
0.329%(−0.07)
Close PriceLast Updated: — ET
52W L: $19.6952W H: $28.35
ACAD NEWS
marketbeat.com
May 19
ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE Growth
ACADIA Pharmaceuticals NASDAQ: ACAD executives used an RBC Capital Markets investor session to outline the company's clinical rationale for remlifanserin in Alzheimer's disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business development priorities.
seekingalpha.com
May 12
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
marketbeat.com
May 12
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
ACADIA Pharmaceuticals NASDAQ: ACAD executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference.
zacks.com
May 7
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.
seekingalpha.com
May 7
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript
zacks.com
May 6
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.11 per share a year ago.
